公开(公告)号：US20160022658A1

公开(公告)日：2016-01-28

申请号：US14877783

申请日：2015-10-07

Applicant: AbbVie Inc.

Inventor： Murali Gopalakrishnan ,  Marie P. Honore ,  Chih-Hung Lee ,  John Malysz ,  Jianguo Ji ,  Tao Li ,  Michael R. Schrimpf ,  Kevin B. Sippy ,  David J. Anderson

IPC: A61K31/4439 ,  A61K31/444 ,  G01N33/94 ,  C07D413/04 ,  C07D413/14 ,  A61K45/06 ,  A61K31/4427 ,  A61K31/4709

CPC classification number: A61K31/4439 ,  A61K31/4245 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4709 ,  A61K45/06 ,  C07D413/04 ,  C07D413/14 ,  G01N33/944 ,  G01N2333/70571 ,  A61K2300/00

Abstract: The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture.

Abstract translation: 本发明涉及包含神经元烟碱性受体配体和α4和bgr2阳性变构调节剂，其使用方法和相关制品的组合物。

公开(公告)号：US08669255B2

公开(公告)日：2014-03-11

申请号：US13627541

申请日：2012-09-26

Applicant: AbbVie Inc.

Inventor： Tao Li ,  Sachin V. Patel ,  Richard J. Perner ,  John T. Randolph ,  Michael R. Schrimpf ,  Kevin R. Woller ,  Zhiren Xia ,  Qingwei Zhang

IPC: A61K31/495

CPC classification number: C07D487/04

Abstract: The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Z1, Z2, Z3, Z4, R1, R2, and R3 are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel inhibitors.

Abstract translation: 本申请涉及：（a）式（I）的化合物及其盐，其中Z 1，Z 2，Z 3，Z 4，R 1，R 2和R 3如说明书中所定义; （b）包含这些化合物和盐的组合物; 和（c）使用这些化合物，盐和组合物的方法，特别是用作钙通道抑制剂。

公开(公告)号：US08648074B2

公开(公告)日：2014-02-11

申请号：US13627536

申请日：2012-09-26

Applicant: AbbVie Inc.

Inventor： Tao Li ,  Sachin V. Patel ,  Richard J. Perner ,  John T. Randolph ,  Michael R. Schrimpf ,  Kevin R. Woller ,  Zhiren Xia ,  Qingwei Zhang

IPC: A61K31/495

CPC classification number: C07D487/04

Abstract: The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Z′, Z″, L2, G2, R1, and R2 are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel blockers.

Abstract translation: 本申请涉及：（a）式（I）的化合物及其盐，其中Z'，Z“，L2，G2，R1和R2如说明书中所定义; （b）包含这些化合物和盐的组合物; 和（c）使用这些化合物，盐和组合物的方法，特别是用作钙通道阻滞剂。

公开(公告)号：US20130085141A1

公开(公告)日：2013-04-04

申请号：US13627536

申请日：2012-09-26

Applicant: ABBVie Inc.

Inventor： Tao Li ,  Sachin V. Patel ,  Richard J. Perner ,  John T. Randolph ,  Michael R. Schrimpf ,  Kevin R. Woller ,  Zhiren Xia ,  Qingwei Zhang

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Z′, Z″, L2, G2, R1, and R2 are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel blockers.

Abstract translation: 本申请涉及：（a）式（I）化合物及其盐，其中Z'，Z“，L2，G2，R1和R2如说明书中所定义; （b）包含这些化合物和盐的组合物; 和（c）使用这些化合物，盐和组合物的方法，特别是用作钙通道阻滞剂。

公开(公告)号：US09983218B2

公开(公告)日：2018-05-29

申请号：US15454313

申请日：2017-03-09

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Chih-hung Lee ,  Tao Li ,  Gregory Gfesser ,  Kathleen Mortell ,  Ramin Faghih ,  Diana L. Schmidt ,  Kevin Sippy ,  William H. Bunnelle ,  Marc Scanio ,  Lei Shi ,  Murali Gopalakrishnan ,  Diana L. Donnelly-Roberts ,  Min Hu

IPC: C07D471/18 ,  G01N33/68 ,  C07D487/10 ,  G01N33/50

CPC classification number: G01N33/6896 ,  C07D471/18 ,  C07D487/10 ,  G01N33/5058 ,  G01N2800/2814 ,  G01N2800/30

Abstract: The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：US20130085142A1

公开(公告)日：2013-04-04

申请号：US13627541

申请日：2012-09-26

Applicant: AbbVie Inc.

Inventor： Tao Li ,  Sachin V. Patel ,  Richard J. Perner ,  John T. Randolph ,  Michael R. Schrimpf ,  Kevin R. Woller ,  Zhiren Xia ,  Qingwei Zhang

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Z1, Z2, Z3, Z4, R1, R2, and R3 are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel inhibitors.

Abstract translation: 本申请涉及：（a）式（I）的化合物及其盐，其中Z 1，Z 2，Z 3，Z 4，R 1，R 2和R 3如说明书中所定义; （b）包含这些化合物和盐的组合物; 和（c）使用这些化合物，盐和组合物的方法，特别是用作钙通道抑制剂。

公开(公告)号：US20150353550A1

公开(公告)日：2015-12-10

申请号：US14715330

申请日：2015-05-18

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Chih-Hung Lee ,  Tao Li ,  Gregory A. Gfesser ,  Kathleen H. Mortell ,  Ramin Faghih ,  Diana L. Nersesian ,  Kevin B. Sippy ,  William H. Bunnelle ,  Marc Scanio ,  Lei Shi ,  Murali Gopalakrishnan ,  Diana L. Donnelly-Roberts ,  Min Hu

IPC: C07D471/18

CPC classification number: G01N33/5058 ,  C07D471/18 ,  C07D487/10 ,  C07D487/18 ,  G01N33/6896 ,  G01N2800/28 ,  G01N2800/30

Abstract: The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract translation: 本申请涉及式（I），（II），（III），（IV），（V）或（VI）的吲哚和二氢吲哚衍生物，其中a，R1，R2，R3，R4，R5， V，W，X，Y和Z如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

公开(公告)号：US20150158867A1

公开(公告)日：2015-06-11

申请号：US14624517

申请日：2015-02-17

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Diana L. Nersesian ,  Kevin B. Sippy ,  Jianguo Ji ,  Tao Li ,  Marc Scanio ,  Lei Shi ,  Chih-Hung Lee ,  William H. Bunnelle ,  Geoff G.Z. Zhang ,  Paul J. Brackemeyer ,  Shuang Chen ,  Rodger F. Henry

IPC: C07D471/18 ,  A61K31/439 ,  A61K31/501 ,  A61K31/444 ,  C07C309/29 ,  A61K31/095

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Abstract translation: 本发明涉及作为氮杂金刚烷衍生物的化合物，特别是醚取代或胺取代的氮杂金刚烷衍生物及其盐和前体药物，包含这些化合物的组合物，使用这些化合物和组合物的方法，制备这些化合物的方法以及在此过程中获得的中间体 。

公开(公告)号：US08987453B2

公开(公告)日：2015-03-24

申请号：US13653192

申请日：2012-10-16

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Diana L. Nersesian ,  Kevin B. Sippy ,  Jianguo Ji ,  Tao Li ,  Marc Scanio ,  Lei Shi ,  Chih-Hung Lee ,  William H. Bunnelle ,  Geoff G. Z. Zhang ,  Paul J. Brackemeyer ,  Shuang Chen ,  Rodger F. Henry

IPC: C07D471/18 ,  A61K45/06 ,  A61K31/444 ,  C07D471/08 ,  C07F5/02 ,  A61K31/439 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Abstract translation: 本发明涉及作为氮杂金刚烷衍生物的化合物，特别是醚取代或胺取代的氮杂金刚烷衍生物及其盐和前体药物，包含这些化合物的组合物，使用这些化合物和组合物的方法，制备这些化合物的方法以及在此过程中获得的中间体 。

公开(公告)号：US20130096132A1

公开(公告)日：2013-04-18

申请号：US13653192

申请日：2012-10-16

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Diana L. Nersesian ,  Kevin B. Sippy ,  Jianguo Ji ,  Tao Li ,  Marc Scanio ,  Lei Shi ,  Chih-Hung Lee ,  William H. Bunnelle ,  Geoff G.Z. Zhang ,  Paul J. Brackemeyer ,  Shuang Chen ,  Rodger F. Henry

IPC: C07D471/18 ,  A61K45/06 ,  A61K31/501 ,  A61K31/496 ,  A61K31/506 ,  A61K31/497 ,  A61K31/439 ,  A61K31/444

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.